Fig. 2.

Exosomes derived from MI alter tumor sensitivity to ferroptosis in vivo. a, b Representative images of echocardiograph and the statistical analyses of EF% and FS% (N = 6/group); c Exosome morphology was characterized by transmission electron microscope (TEM) in isolated from plasma in sham operated mouse; d Exosome marker CD63, CD81 and TSG101 protein levels were detected in plasma, exosome and supernatant isolated from sham mice by Western blot; e Particle size distribution was determined by Nanosight tracking analysis (N = 3/group); f Schematic time-line of in vivo cell transplantation experiment; g–i Representative images of tumors with the corresponding (h) tumor volumes and (i) tumor weights in nude mice bearing LLC cells with erastin treatment or sham/MI exosomes administration. (N = 10/group). The exosomes (1 × 10⁹ particles) were administered intratumorally to mice every other day for 3 weeks at day 3 after tumor cells inoculation; j H&E and representative immunohistochemical images and statistical analysis of Ki67, 4-HNE staining from subcutaneous xenograft tissues in LLC tumor-bearing model. Quantification of Ki67, 4-HNE intensity as % of total area (Bar: 20 μm) (N = 5/group). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001